| __timestamp | Eli Lilly and Company | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 1499100000 |
| Thursday, January 1, 2015 | 6533000000 | 1923500000 |
| Friday, January 1, 2016 | 6452000000 | 2351400000 |
| Sunday, January 1, 2017 | 6588100000 | 2564000000 |
| Monday, January 1, 2018 | 5975100000 | 2397300000 |
| Tuesday, January 1, 2019 | 6213800000 | 2503400000 |
| Wednesday, January 1, 2020 | 6121200000 | 3344600000 |
| Friday, January 1, 2021 | 6431600000 | 4529200000 |
| Saturday, January 1, 2022 | 6440400000 | 4179100000 |
| Sunday, January 1, 2023 | 6941200000 | 4650100000 |
| Monday, January 1, 2024 | 8593800000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Eli Lilly and Company and Viatris Inc. have demonstrated contrasting approaches to optimizing these costs. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a relatively stable trend, averaging around $6.4 billion annually, with a slight increase of approximately 5% in 2023. In contrast, Viatris Inc. has experienced a more dynamic shift, with SG&A expenses rising by over 200% from 2014 to 2023, peaking at $4.65 billion. This significant increase reflects Viatris's strategic investments and restructuring efforts. As these companies continue to navigate the evolving market, their ability to manage SG&A costs effectively will be pivotal in sustaining their competitive edge.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Zoetis Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Viatris Inc. or CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: Viatris Inc. vs ACADIA Pharmaceuticals Inc. Trends and Insights
Comparing SG&A Expenses: Viatris Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Viatris Inc. vs Veracyte, Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Galapagos NV